查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930123

全球麻疹-腮腺炎-德國麻疹 (MMR) 疫苗市場：市場規模、市場佔有率、成長率、產業分析、類型、應用和區域分析、未來預測 (2026-2034)

Measles, Mumps, Rubella (MMR) Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 請詢問到貨日

價格

麻疹-腮腺炎-德國麻疹 (MMR) 疫苗市場成長驅動因子

由於疾病發生率上升、疫苗接種覆蓋率擴大以及全球各國政府的持續支持，全球麻疹-腮腺炎-德國麻疹 (MMR) 疫苗市場正經歷顯著增長。根據 Fortune Business Insights 的數據顯示，2025 年全球 MMR 疫苗市場規模為 51.7 億美元。預計該市場將從 2026 年的 55.9 億美元成長到 2034 年的 144.3 億美元，預測期內複合年增長率 (CAGR) 為 12.59%。 預計到2025年，北美將以38.02%的市場佔有率引領全球市場，這主要得益於強有力的疫苗接種計劃和高接種率。

麻疹、腮腺炎和德國麻疹是傳染性極強且可能危及生命的病毒性疾病。麻疹、腮腺炎、德國麻疹合併疫苗（MMR疫苗）是一種含有減毒活病毒的聯合疫苗，通常分兩劑接種，分別在12個月和4歲時接種。這些疫苗的高效性、強烈的免疫原性反應和長期保護作用使其成為許多國家國家免疫計畫的重要組成部分。

市場動態

市場驅動因素

政府主導的措施和疫苗接種計劃的擴展是推動麻疹、腮腺炎、德國麻疹聯合疫苗市場發展的關鍵因素。美國和印度等國家已將麻疹、腮腺炎、德國麻疹聯合疫苗納入其國家免疫規劃（NIP），確保民眾能夠免費或享有補助接種。 世界衛生組織 (WHO)、聯合國兒童基金會 (UNICEF) 和全球疫苗免疫聯盟 (Gavi) 等國際組織的支持顯著擴大了疫苗覆蓋範圍。根據美國疾病管制與預防中心 (CDC) 稱，截至 2025 年 1 月，單劑麻疹、腮腺炎、德國麻疹 (MMR) 疫苗對麻疹的有效率為 93.0%，對腮腺炎的有效率為 72%，對德國麻疹的有效率為 97%，這增強了人們對該疫苗有效性的信心。

市場限制因子

疫苗猶豫仍是限制市場成長的主要因素。錯誤訊息、宗教信仰和對副作用的擔憂等因素降低了疫苗的接受度。 2023 年發布的一份報告指出，家長擔心接種疫苗後會出現發燒和注射部位疼痛，導致某些人延遲接種疫苗。

市場機會

技術進步，特別是微陣列貼片 (MAP) 的開發，帶來了可觀的成長機會。 這些無針、耐熱的給藥系統提高了患者的依從性，簡化了疫苗接種流程，尤其是在中低收入國家。聯合國兒童基金會和世界衛生組織積極支持MAP的研發，該系統展現出巨大的未來潛力。

市場挑戰

維持冷鏈仍然是一項重大挑戰。麻疹、腮腺炎、德國麻疹疫苗對溫度高度敏感，不當的儲存和運輸會導致疫苗浪費和效力降低。偏遠地區薄弱的冷鏈基礎設施持續阻礙市場的最佳擴張。

市場趨勢

影響市場的關鍵趨勢是公私合作的興起。政府、非政府組織和製藥公司之間的合作正在提高疫苗的可及性，加強供應鏈，並彌補免疫接種缺口。全球麻疹疫情的再次爆發正在推動進一步的協調疫苗接種工作。

市場區隔分析

依類型

2024年，聯合疫苗因其便利性、成本效益和減少注射負擔而佔市場主導地位。麻疹-腮腺炎-德國麻疹二聯疫苗（MMR II）和普利樂（PRIORIX）等產品有助於提高患者依從性。同時，單聯疫苗因其針對特定疾病的用途而維持了相當大的市場佔有率。

依產品

2024年，麻疹-腮腺炎-德國麻疹二聯疫苗（MMR II）佔最大的市場佔有率，這得益於其數十年的使用歷史以及在各國免疫規劃中的廣泛應用。普利樂（PRIORIX）由於獲得美國FDA批准並在100多個國家獲得許可，預計將實現強勁成長。

依給藥途徑

2024年，皮下注射因其監管建議和患者舒適度而佔市場主導地位。 由於其強大的免疫原性和不斷擴大的批准範圍，肌注給藥途徑也保持了相當大的市場佔有率。

依年齡組別劃分

由於強制性兒童疫苗接種計劃，兒科市場佔主導地位。成人市場也穩定成長，這得益於未接種疫苗或部分接種疫苗的成年人意識的提高。

依通路劃分

由於國家疫苗接種計劃的大規模採購，政府供應商在2024年佔了最大的市場佔有率。隨著疫苗接種點的增加，醫院和零售藥局預計將顯著成長。

區域展望

北美地區得益於高疫苗接種率和健全的公共衛生基礎設施，預計2025年和2026年的收入將分別達到19.7億美元和21.5億美元。

由於歐盟/歐洲經濟區國家實施強制性兩劑疫苗接種制度，歐洲仍佔較大佔有率。

亞太地區預計將實現最快成長，這得益於龐大的人口基數和政府資助的疫苗接種計劃，尤其是在印度。

拉丁美洲和中東/非洲地區由於公眾意識的提高和疫苗可及性的改善，正經歷穩步增長。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 主要國家和地區主要疾病的發生率/盛行率（2025 年）
  • 主要公司產品線分析
  • 主要國家疫苗接種覆蓋率概覽
  • 麻疹、腮腺炎、德國麻疹 (MMR) 疫苗技術進展
  • 主要公司新產品發布
  • 主要產業趨勢：併購、業務合作等等。

第五章 全球麻疹-腮腺炎-德國麻疹 (MMR) 疫苗市場分析：洞察與預測 (2021-2034)

  • 市場分析、洞察與預測：依類型
    • 單價疫苗
    • 聯合疫苗
  • 市場分析、洞察與預測：依產品
    • MMR II
    • PRIORIX
    • MMR Pro
    • Tresivac
    • 其他
  • 市場分析、洞察與預測：依給藥途徑
    • 肌肉注
    • 皮下注射
    • 其他
  • 市場分析、洞察與預測：依年齡組別
    • 兒科
    • 成人
  • 市場分析、洞察與預測：依通路劃分
    • 醫院和零售藥局
    • 政府供應商
    • 其他
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美麻疹-腮腺炎-德國麻疹 (MMR) 疫苗市場分析：洞察與預測 (2021-2034)

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲麻疹-腮腺炎-德國麻疹 (MMR) 疫苗市場分析：洞察與預測 (2021-2034)

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 歐洲其他地區

第八章 亞太地區麻疹-腮腺炎-德國麻疹 (MMR) 疫苗市場分析：洞察與預測 (2021-2034)

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲麻疹-腮腺炎-德國麻疹 (MMR) 疫苗市場分析：洞察與預測 (2021-2034)

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東與非洲麻疹-腮腺炎-德國麻疹 (MMR) 疫苗市場分析：洞察與預測 (2021-2034)

  • 依國家劃分
    • 海灣合作委員會 (GCC) 國家
    • 南非
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析 (2025)
  • 公司公司簡介
    • GSK plc.
    • Serum Institute of India Pvt. Ltd.
    • Merck &Co., Inc.
    • Indian Immunologicals Limited
    • Zydus Lifesciences Limited
    • Takeda Pharmaceutical Company Limited
    • BIOLOGICAL E. LIMITED
    • Invivyd, Inc.
    • Daiichi Sankyo Company, Limited
Product Code: FBI113753

Growth Factors of measles, mumps, rubella (MMR) vaccines Market

The global measles, mumps, rubella (MMR) vaccines market is witnessing strong expansion due to rising disease incidence, growing immunization coverage, and sustained government support worldwide. According to Fortune Business Insights, the global MMR vaccines market size was valued at USD 5.17 billion in 2025. The market is projected to grow from USD 5.59 billion in 2026 to USD 14.43 billion by 2034, registering a CAGR of 12.59% during the forecast period. North America dominated the global market with a share of 38.02% in 2025, supported by robust immunization programs and high vaccine uptake.

Measles, mumps, and rubella are highly contagious and potentially life-threatening viral diseases. MMR vaccines are combination vaccines containing live attenuated viruses, administered in two doses-typically at 12 months and again at 4 years of age. The high potency, strong immunogenic response, and long-term protection offered by these vaccines have made them essential components of national immunization schedules across multiple countries.

Market Dynamics

Market Drivers

Rising government initiatives and immunization programs are major drivers of the MMR vaccines market. Countries such as the U.S. and India have incorporated MMR vaccines into their National Immunization Programs (NIP), ensuring free or subsidized access. Support from international organizations such as WHO, UNICEF, and Gavi has significantly expanded vaccine coverage. According to the CDC, as of January 2025, one dose of the MMR vaccine is 93.0% effective against measles, 72% against mumps, and 97% against rubella, reinforcing strong confidence in vaccine effectiveness.

Market Restraints

Vaccine hesitancy remains a key restraint limiting market growth. Factors such as misinformation, religious beliefs, and fear of side effects reduce vaccine acceptance. Reports published in 2023 highlighted parental concerns regarding post-vaccination fever and injection-site pain, which continue to delay immunization in certain populations.

Market Opportunities

Technological advancements, particularly the development of microarray patches (MAPs), offer promising growth opportunities. These needle-free, thermostable delivery systems improve patient compliance and simplify vaccine administration, especially in low- and middle-income countries. UNICEF and WHO have actively supported MAP development, indicating strong future potential.

Market Challenges

Cold chain maintenance remains a critical challenge. MMR vaccines are highly temperature-sensitive, and improper storage or transportation can lead to vaccine wastage and reduced efficacy. Weak cold chain infrastructure in remote regions continues to hinder optimal market expansion.

Market Trends

A key trend shaping the market is the rise in public-private partnerships. Collaboration between governments, NGOs, and pharmaceutical companies is improving vaccine accessibility, strengthening supply chains, and addressing immunization gaps. Increasing measles resurgence globally has further intensified coordinated immunization efforts.

Segmentation Analysis

By Type

The combination vaccine segment dominated the market in 2024 due to convenience, cost-effectiveness, and reduced injection burden. Products such as M-M-R II and PRIORIX support higher patient compliance. The standalone segment maintained a notable share due to disease-specific usage.

By Product

M-M-R II held the largest market share in 2024, driven by decades-long usage and widespread inclusion in national immunization programs. PRIORIX is expected to grow at a strong pace due to U.S. FDA approval and licensing across more than 100 countries.

By Route of Administration

The subcutaneous route dominated the market in 2024, supported by regulatory recommendations and patient comfort. The intramuscular segment also held a significant share due to strong immunogenicity and expanded approvals.

By Age Group

The pediatric segment led the market owing to mandatory childhood vaccination schedules. The adult segment is growing steadily as awareness increases among unvaccinated or partially vaccinated adults.

By Distribution Channel

Government suppliers accounted for the largest share in 2024 due to large-scale procurement for national immunization programs. Hospital and retail pharmacies are expected to grow significantly with expanding vaccination access points.

Regional Outlook

North America generated revenues of USD 1.97 billion in 2025 and USD 2.15 billion in 2026, driven by high vaccination coverage and strong public health infrastructure.

Europe maintained a significant share due to mandatory two-dose schedules across EU/EEA countries.

Asia Pacific is witnessing the fastest growth, supported by large population bases and government-funded vaccination programs, particularly in India.

Latin America and the Middle East & Africa are growing steadily with increasing awareness and improved vaccine access.

Competitive Landscape

The market is led by GSK plc., Merck & Co., Inc., and Serum Institute of India Pvt. Ltd., supported by strong R&D pipelines and global distribution networks. Other prominent players include Indian Immunologicals Limited, Zydus Lifesciences Limited, Takeda Pharmaceutical Company Limited, and Biological E. Limited.

Conclusion

In conclusion, the global measles, mumps, rubella (MMR) vaccines market is set for robust growth from 2025 to 2034, expanding from USD 5.17 billion in 2025 to USD 14.43 billion by 2034. Strong government initiatives, high vaccine efficacy, and expanding immunization coverage are key growth drivers. However, vaccine hesitancy and cold chain challenges remain critical concerns. Continued innovation, public-private collaboration, and investment in advanced delivery technologies will be essential to sustaining long-term market growth.

Segmentation By Type

  • Standalone
  • Combination

By Product

  • M-M-R II
  • PRIORIX
  • M-M-RvaxPro
  • Tresivac
  • Others

By Route of Administration

  • Intramuscular
  • Subcutaneous
  • Others

By Age Group

  • Adult
  • Pediatric

By Distribution Channel

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

By Region

  • North America (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Type, Product, Route of Administration, Age Group, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Incidence/Prevalence of Key Diseases, By Key Countries/Regions, 2025
  • 4.2. Pipeline Analysis, By Key Players
  • 4.3. Overview: Immunization Coverage, By Key Countries
  • 4.4. Technological Advancements in the MMR Vaccines
  • 4.5. New Product Launches, By Key Players
  • 4.6. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships

5. Global Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Type
    • 5.1.1. Standalone
    • 5.1.2. Combination
  • 5.2. Market Analysis, Insights and Forecast - By Product
    • 5.2.1. M-M-R II
    • 5.2.2. PRIORIX
    • 5.2.3. M-M-RvaxPro
    • 5.2.4. Tresivac
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Intramuscular
    • 5.3.2. Subcutaneous
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Age Group
    • 5.4.1. Pediatrics
    • 5.4.2. Adults
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital & Retail Pharmacies
    • 5.5.2. Government Suppliers
    • 5.5.3. Others
  • 5.6. Market Analysis, Insights and Forecast - By Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Type
    • 6.1.1. Standalone
    • 6.1.2. Combination
  • 6.2. Market Analysis, Insights and Forecast - By Product
    • 6.2.1. M-M-R II
    • 6.2.2. PRIORIX
    • 6.2.3. M-M-RvaxPro
    • 6.2.4. Tresivac
    • 6.2.5. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Intramuscular
    • 6.3.2. Subcutaneous
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Age Group
    • 6.4.1. Pediatrics
    • 6.4.2. Adults
  • 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.5.1. Hospital & Retail Pharmacies
    • 6.5.2. Government Suppliers
    • 6.5.3. Others
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Type
    • 7.1.1. Standalone
    • 7.1.2. Combination
  • 7.2. Market Analysis, Insights and Forecast - By Product
    • 7.2.1. M-M-R II
    • 7.2.2. PRIORIX
    • 7.2.3. M-M-RvaxPro
    • 7.2.4. Tresivac
    • 7.2.5. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Intramuscular
    • 7.3.2. Subcutaneous
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Age Group
    • 7.4.1. Pediatrics
    • 7.4.2. Adults
  • 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.5.1. Hospital & Retail Pharmacies
    • 7.5.2. Government Suppliers
    • 7.5.3. Others
  • 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.6.1. U.K.
    • 7.6.2. Germany
    • 7.6.3. France
    • 7.6.4. Spain
    • 7.6.5. Italy
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Type
    • 8.1.1. Standalone
    • 8.1.2. Combination
  • 8.2. Market Analysis, Insights and Forecast - By Product
    • 8.2.1. M-M-R II
    • 8.2.2. PRIORIX
    • 8.2.3. M-M-RvaxPro
    • 8.2.4. Tresivac
    • 8.2.5. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Intramuscular
    • 8.3.2. Subcutaneous
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Age Group
    • 8.4.1. Pediatrics
    • 8.4.2. Adults
  • 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.5.1. Hospital & Retail Pharmacies
    • 8.5.2. Government Suppliers
    • 8.5.3. Others
  • 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. Southeast Asia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Type
    • 9.1.1. Standalone
    • 9.1.2. Combination
  • 9.2. Market Analysis, Insights and Forecast - By Product
    • 9.2.1. M-M-R II
    • 9.2.2. PRIORIX
    • 9.2.3. M-M-RvaxPro
    • 9.2.4. Tresivac
    • 9.2.5. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Intramuscular
    • 9.3.2. Subcutaneous
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Age Group
    • 9.4.1. Pediatrics
    • 9.4.2. Adults
  • 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.5.1. Hospital & Retail Pharmacies
    • 9.5.2. Government Suppliers
    • 9.5.3. Others
  • 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Type
    • 10.1.1. Standalone
    • 10.1.2. Combination
  • 10.2. Market Analysis, Insights and Forecast - By Product
    • 10.2.1. M-M-R II
    • 10.2.2. PRIORIX
    • 10.2.3. M-M-RvaxPro
    • 10.2.4. Tresivac
    • 10.2.5. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Intramuscular
    • 10.3.2. Subcutaneous
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Age Group
    • 10.4.1. Pediatrics
    • 10.4.2. Adults
  • 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.5.1. Hospital & Retail Pharmacies
    • 10.5.2. Government Suppliers
    • 10.5.3. Others
  • 10.6. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.6.1. GCC
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. GSK plc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Serum Institute of India Pvt. Ltd.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Merck & Co., Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Indian Immunologicals Limited
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Zydus Lifesciences Limited
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Takeda Pharmaceutical Company Limited
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. BIOLOGICAL E. LIMITED
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Invivyd, Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Daiichi Sankyo Company, Limited
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 2: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 4: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 5: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 6: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 7: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 8: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 9: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 10: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 11: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 12: North America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 13: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 14: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 15: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 16: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 17: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 18: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 19: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 20: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 21: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 22: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 23: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 25: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 26: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 27: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 28: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 29: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 31: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 32: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 33: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2021-2034
  • Table 34: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 35: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 36: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Measles, Mumps, Rubella (MMR) Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2025 & 2034
  • Figure 3: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2025 & 2034
  • Figure 5: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2025 & 2034
  • Figure 6: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 7: Global Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Region, 2025 & 2034
  • Figure 8: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 9: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2025
  • Figure 10: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 11: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 12: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 13: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 14: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Product, 2025 & 2034
  • Figure 15: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2025
  • Figure 16: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 17: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 18: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Country, 2025 & 2034
  • Figure 19: North America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Country, 2025
  • Figure 20: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 21: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2025
  • Figure 22: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 23: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 24: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 25: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 26: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Product, 2025 & 2034
  • Figure 27: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2025
  • Figure 28: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 29: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 30: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 31: Europe Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 32: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 33: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2025
  • Figure 34: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 35: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 36: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 37: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 38: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Product, 2025 & 2034
  • Figure 39: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2025
  • Figure 40: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 41: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 42: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 43: Asia Pacific Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 44: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 45: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2025
  • Figure 46: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 47: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 48: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 49: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 50: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Product, 2025 & 2034
  • Figure 51: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2025
  • Figure 52: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 53: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 54: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 55: Latin America Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 56: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Type, 2025 & 2034
  • Figure 57: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Type, 2025
  • Figure 58: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 59: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 60: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Age Group, 2025 & 2034
  • Figure 61: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Age Group, 2025
  • Figure 62: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Product, 2025 & 2034
  • Figure 63: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Product, 2025
  • Figure 64: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 65: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 66: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 67: Middle East & Africa Measles, Mumps, Rubella (MMR) Vaccines Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 68: Global Measles, Mumps, Rubella (MMR) Vaccines Market Share (%), By Company, 2025